Safety and Efficacy of Lutetium‐177 PSMA Radioligand Therapy in Metastatic Castration‐Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study)

[¹⁷⁷Lu]Lu-PSMA-RLT demonstrates clinically meaningful benefits in survival and symptom management with an acceptable safety profile for mCRPC patients with extensive bone metastases. These findings support [¹⁷⁷Lu]Lu-PSMA-RLT as a viable treatment option for this challenging population.